Undercarboxylated Osteocalcin for Frailty Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively treat the complex of disorders associated with aging, including muscle wasting, lung disorders, metabolic disorders, male reproductive disorders, and cognitive disorders, which are collectively known as frailty, as they do not adequately address the underlying hormonal and physiological imbalances.
Innovation Solution
Administration of a pharmaceutical composition comprising undercarboxylated/uncarboxylated osteocalcin, which modulates the OST-PTP signaling pathway or the PTP-1B signaling pathway, thereby reducing phosphorylase expression or activity, increasing the levels of undercarboxylated osteocalcin, and alleviating multiple associated disorders simultaneously.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatment methods are used for aging-related disorders, then individual symptoms may be temporarily managed, but the underlying hormonal and physiological imbalances remain unaddressed, leading to ineffective long-term treatment
Solution Approach 1:
The patent applies universality by using osteocalcin as a single therapeutic agent that simultaneously addresses multiple aging-related disorders including muscle wasting, lung disorders, metabolic disorders, male reproductive disorders, and cognitive disorders. This multi-functional approach treats the root hormonal imbalances rather than managing individual symptoms separately, thereby improving treatment reliability without requiring complex multi-drug regimens
2Reliability
If osteocalcin administration is used to treat multiple disorders simultaneously, then treatment effectiveness improves, but the complexity of the pharmaceutical composition and administration protocol increases
Solution Approach 1:
The pharmaceutical composition utilizes osteocalcin's multi-functional properties to treat diverse aging-related disorders through a single agent, addressing muscle wasting, lung disorders, metabolic disorders, male reproductive disorders, and cognitive disorders simultaneously. This approach improves treatment reliability while avoiding the complexity of multiple separate medications
Solution Approach 2:
The patent employs parameter changes by administering osteocalcin at specific dosages (e.g., 1-1000 µg/day) and in particular forms (undercarboxylated/uncarboxylated) to optimize therapeutic effectiveness across multiple disorder types, thereby managing composition complexity through controlled parameter specification
Data Source
AI summary
Methods and compositions for treating frailty in mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-1B signaling pathway involving gamma-carboxylase and osteocalcin, e.g., by administration of undercarboxylated/uncarboxylated osteocalcin. The methods comprise alleviating at least one of: muscle wasting or a lung disorder while also alleviating at least one of: a metabolic disorder, a male reproductive disorder, or a cognitive disorder.